| Name |
|---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
Atossa Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of proprietary medicines for oncology, with a focus on breast cancer and related conditions. The company's lead product candidate, oral (Z)-endoxifen, is...
Benzinga Rankings give you vital metrics on any stock – anytime.
You can purchase shares of Atossa Therapeutics (NASDAQ:ATOS) through any online brokerage.
Other companies in Atossa Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Moderna Inc (NASDAQ:MRNA).
Atossa Therapeutics has a consensus price target of $20.50.
The stock price for Atossa Therapeutics (NASDAQ: ATOS) is $2.33 last updated October 13, 2026 at 12:33 PM EDT.
There are no upcoming dividends for Atossa Therapeutics.
Atossa Therapeutics does not have any upcoming earnings scheduled.
There is no upcoming split for Atossa Therapeutics.
Atossa Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
